Category: RT Now

Combined IPF Treatment Awaiting US Patent Approval

PTL-202, Pacific’s lead pipeline product for idiopathic pulmonary fibrosis, has completed preclinical and Phase I clinical testing, with the combination drug’s first clinical test demonstrating encouraging results that may result in patients requiring much lower doses.

Read More
Loading